Liver resection is the standard curative treatment for liver cancer. Advances in surgical
techniques over the last 30 years, including the preoperative assessment of the future liver …

Background Combination conversion therapies afforded curative surgery chance for initially
unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the …

Background A single hepatocellular carcinoma (HCC) is a good indication for hepatic
resection regardless of tumor size, but the surgical indications for cases with multiple HCCs …

Background/Aim: Conversion surgery (CS) following atezolizumab plus bevacizumab (Atez+
Bev) is a treatment strategy for unresectable hepatocellular carcinoma (UR-HCC). Herein …

It has been reported that patients with macroscopic vascular invasion accompanying
hepatocellular carcinoma have a poor prognosis. Modern molecular therapy with …

Background: The efficacy of molecular-targeted agents (MTAs) has been demonstrated in
recent years. However, the results of multidisciplinary treatment including hepatic resection …

Background/Aim: Sorafenib was previously the only targeted therapy for hepatocellular
carcinoma (HCC). However, pharmaceutical therapy for HCC has undergone remarkable …

Background: Multiple bilateral lung metastases secondary to hepatocellular carcinoma
(HCC) are mainly treated with molecular therapy. Atezolizumab plus bevacizumab can …

Hepatocellular carcinoma (HCC) is a common primary liver cancer with a high incidence
and mortality. Members of the growth-arresting-specific 2 (GAS2) family are involved in …

Abstract Background/Aim: Hepatocellular carcinoma (HCC) with bile duct tumor thrombus
(BDTT) is highly malignant; therefore, continual, multidisciplinary treatments are essential …